PROMISE Substudy Results, Published in the American Heart Journal, Provide Independent Validation of the Clinical Value of the Corus(R) CAD Blood Test to Accurately Identify Patients with Obstructive CAD

REDWOOD CITY, CA--(Marketwired - Feb 6, 2017) - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced today the publication of a peer-reviewed substudy of the National Heart, Lung and Blood Institute (NHLBI)-funded PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) trial in the American Heart Journal, which assessed the Corus CAD test's ability to predict future clinical events.¹ Previously validated for the detection of obstructive* coronary artery disease (CAD) with a 96% negative predictive value and 89% sensitivity, Corus CAD is a simple blood test, incorporating age, sex, and gene expression measurements into a single score (1-40 scale) that indicates the current likelihood of obstructive CAD.²

"The PROMISE study findings are important because they provide clinicians with additional information regarding their patients with suspected obstructive CAD using a non-invasive blood test that come from a pragmatic clinical trial setting," said Deepak Voora, M.D., lead author and substudy investigator, Associate Professor of Medicine and member of the Duke Center for Applied Genomics & Precision Medicine in the Department of Medicine, Duke University School of Medicine. "What many don't realize is that it is often difficult to diagnose CAD because many patients do not have typical symptoms. Our substudy, which included more than 2,000 patients, demonstrated that patients with low scores not only had a low likelihood of obstructive CAD but also were at lower risk for undergoing revascularization in the near term. Study results suggest this test could provide additional assurance for clinicians to pursue alternate causes of symptoms and to defer the need for advanced cardiac testing in patients with low scores."

"The results of the PROMISE substudy reinforce the clinical validity of the Corus CAD test over a range of scores," said Mark Monane, M.D., FACP, Chief Medical Officer of CardioDx. "The PROMISE substudy, with a median patient follow-up of greater than two years, highlights and strengthens the clinical value of the Corus CAD blood test and its ability to help clinicians safely and accurately identify patients who may be at a low or elevated risk of obstructive CAD. The totality of Corus CAD data to date provides the key stakeholders -- patients, physicians and payers -- with a broad range of evidence needed in order to integrate the test into the care and management of patients presenting with symptoms suggestive of obstructive CAD."